Critical Press Coverage Somewhat Unlikely to Impact Obseva (NASDAQ:OBSV) Share Price

News headlines about Obseva (NASDAQ:OBSV) have trended negative recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Obseva earned a daily sentiment score of -0.29 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.6914095414626 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Obseva (NASDAQ:OBSV) traded up $0.72 on Wednesday, hitting $12.59. The stock had a trading volume of 11,471 shares, compared to its average volume of 38,225. Obseva has a fifty-two week low of $5.00 and a fifty-two week high of $14.69.

Obseva (NASDAQ:OBSV) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.01). The company’s revenue for the quarter was up NaN% on a year-over-year basis. research analysts predict that Obseva will post -2.31 earnings per share for the current year.

Several research firms recently weighed in on OBSV. BMO Capital Markets began coverage on Obseva in a research report on Monday, December 4th. They set an “outperform” rating and a $20.00 price target on the stock. HC Wainwright set a $25.00 target price on Obseva and gave the stock a “buy” rating in a research report on Thursday, January 4th. Royal Bank of Canada reissued a “buy” rating and set a $22.00 price objective on shares of Obseva in a report on Thursday, November 2nd. Finally, Zacks Investment Research lowered Obseva from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Obseva has an average rating of “Buy” and a consensus price target of $19.00.

COPYRIGHT VIOLATION WARNING: “Critical Press Coverage Somewhat Unlikely to Impact Obseva (NASDAQ:OBSV) Share Price” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at

About Obseva

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Insider Buying and Selling by Quarter for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with's FREE daily email newsletter.

Leave a Reply